Australia markets closed
  • ALL ORDS

    7,656.60
    -79.20 (-1.02%)
     
  • AUD/USD

    0.7213
    +0.0028 (+0.39%)
     
  • ASX 200

    7,332.50
    -76.30 (-1.03%)
     
  • OIL

    86.60
    +1.17 (+1.37%)
     
  • GOLD

    1,818.90
    +6.50 (+0.36%)
     
  • BTC-AUD

    58,176.76
    -181.04 (-0.31%)
     
  • CMC Crypto 200

    995.73
    -13.65 (-1.35%)
     

The Monster Business Lurking Behind Fulgent's COVID Results

·3-min read
The Monster Business Lurking Behind Fulgent's COVID Results
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Like many companies, Fulgent Genetics (NASDAQ: FLGT) has been labeled a "pandemic stock" by some investors. In the most recent quarter, 82% of Fulgent's revenue came from COVID-19 tests. In the most recent quarter, Fulgent's revenue grew to $126 million, a 124% increase over the third quarter of 2020.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting